Tobacco Dependence Clinical Trial
Official title:
UW Withdraw From Tobacco Study: Enhancing and Evaluating Tobacco Withdrawal Assessment Psychometrics and Validity
Verified date | November 2023 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It is of considerable scientific and clinical importance to assess tobacco withdrawal accurately since withdrawal severity is highly determinant of smoking cessation success. In addition, smoking cessation pharmacotherapy produces its effects on smoking abstinence by suppressing such symptoms. However, in order to ensure that a measure of tobacco withdrawal is sensitive to severe withdrawal, it is essential to examine a period of unmedicated abstinence. The current study aims to validate, and possibly enhance, a revised Wisconsin Smoking Withdrawal Scale long and brief version for use in research and clinical settings. Two hundred adults who smoke cigarettes daily and report a desire to quit smoking will be enrolled. This is a treatment-delay, one-group clinical trial that is intended to enhance the assessment of tobacco withdrawal amongst participants who try to quit smoking with delayed use of cessation medication. Participants will not receive any pharmacotherapy during the first 1 week of their quit attempt and will initiate 8 weeks of combination nicotine replacement therapy (C-NRT; nicotine patch + nicotine mini-lozenge) starting 1 week past the target quit day (TQD). Participants will receive 4 counseling sessions as well (1 pre-quit, 3 post-quit). Participants will complete 4 weeks of ecological momentary assessment (EMA) smartphone surveys including a 2-week baseline (starting TQD-14) and 2-week post-TQD (1-week un-medicated, 1-week using C-NRT).
Status | Completed |
Enrollment | 232 |
Est. completion date | September 21, 2022 |
Est. primary completion date | September 21, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 21 Years and older |
Eligibility | Inclusion Criteria: - Smoke =5 cigarettes per day for past year - =21 years old - Able to read and write English - Desire to quit smoking - Not currently engaged in cessation treatment - Eligible to use combination nicotine replacement therapy - Willing and able to attend study visits - Have reliable smartphone access - Not currently pregnant, trying to get pregnant, or breastfeeding - Willing to respond to ecological momentary assessment prompts and other study activities - Baseline breath carbon monoxide (CO) =5ppm Exclusion Criteria: - Used pipe tobacco, cigars, snuff, or chew more than twice in the past week - Used e-cigarette, vaping, or any other electronic nicotine delivery product more than twice in the past week - Unwilling to try to abstain from all non-medicinal nicotine use (including e-cigarettes) for the duration of the Cessation Phase (other than nicotine replacement therapy provided by the study) - Currently taking varenicline or bupropion - Allergy to adhesive tape - Previous reaction to the nicotine patch or mini-lozenge that prevented them from continuing to use it - Unwilling to use study approved methods of birth control while taking study medication and for 1 month after discontinuing study medication [only for women of child-bearing potential] - Hospitalized for a stroke, heart attack, congestive heart failure, ulcers, or diabetes within the last year - History of seizure within the last year - Diagnosis of and/or treatment for schizophrenia, other psychotic disorders, or bipolar disorder within the last 5 years - End-stage renal disease - Suicide attempt or suicidal ideation within the last 12 months - Severe hypertension > 180/100 mmHg |
Country | Name | City | State |
---|---|---|---|
United States | Center for Tobacco Research and Intervention | Madison | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Total Score on Wisconsin Smoking Withdrawal Scale2 Long (WSWS2-L) | Self-reported withdrawal symptom severity in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2(WSWS-2) Long Version.
WSWS-2 consists of 19 items. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. Mean score from 1-7 is reported. Higher scores indicate more severe withdrawal symptoms. |
pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Primary | Change in Wisconsin Smoking Withdrawal Scale2 Brief Score | Self-reported withdrawal symptom severity in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2(WSWS-2) Brief Version.
WSWS-2 consists of 6 items. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. Higher scores indicate more severe withdrawal symptoms. |
pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Secondary | Change in WSWS2-L Subscale Score : Craving | Self-reported withdrawal symptom severity subscales (negative affect, craving, hunger, sleep, restlessness, concentration) in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2 Long Version. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. | pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Secondary | Change in WSWS2-L Subscale Score : Negative Affect | Self-reported withdrawal symptom severity subscales (negative affect, craving, hunger, sleep, restlessness, concentration) in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2 Long Version. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. | pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Secondary | Change in WSWS2-L Subscale Score : Concentration | Self-reported withdrawal symptom severity subscales (negative affect, craving, hunger, sleep, restlessness, concentration) in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2 Long Version. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. | pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Secondary | Change in WSWS2-L Subscale Score : Sleep Problems | Self-reported withdrawal symptom severity subscales (negative affect, craving, hunger, sleep, restlessness, concentration) in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2 Long Version. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. | pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Secondary | Change in WSWS2-L Subscale Score: Hunger | Self-reported withdrawal symptom severity subscales (negative affect, craving, hunger, sleep, restlessness, concentration) in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2 Long Version. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. | pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Secondary | Change in WSWS2-L Subscale Score : Restlessness | Self-reported withdrawal symptom severity subscales (negative affect, craving, hunger, sleep, restlessness, concentration) in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2 Long Version. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. | pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Secondary | 9-Week Point-Prevalence Abstinence: Number of Participants Who Were Abstinent | Biochemically confirmed self-reported total abstinence from any cigarette use (even a single puff) for the seven days preceding the target follow up day, confirmed with carbon monoxide reading of less than or equal to 5 ppm. | 9 weeks after quit date | |
Secondary | Change in Total Score on Minnesota Tobacco Withdrawal Scale (MTWS) | Self-reported withdrawal symptom severity in the last 24 hours using the Minnesota Tobacco Withdrawal Scale (MTWS). MTWS consists of 17 items. Mean score from 0 to 4 is reported. Higher scores indicate more severe withdrawal symptoms. | pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) | |
Secondary | Change in WSWS2-L Subscale Score: Anhedonia | Exploratory subscale of the WSWS2-L, self-reported withdrawal symptom severity subscales (negative affect, craving, hunger, sleep, restlessness, concentration) in the last 24 hours using the Wisconsin Smoking Withdrawal Scale 2 Long Version. Each item answers on a scale from 1=not at all to 7=extremely, how much a participant has been bothered in the last 24 hours. | pre-quit (2 weeks, 1 week, 1-3 days) and post-quit (1-2 days, 1 week, 2 weeks) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01928719 -
Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status
|
N/A | |
Completed |
NCT01995123 -
Behavioral Activation for Smoking Cessation in PTSD
|
N/A | |
Not yet recruiting |
NCT03249428 -
E-Cigarette Inner City RCT
|
N/A | |
Recruiting |
NCT02564289 -
Cardiovascular Effects of Chronic Snus Use
|
N/A | |
Completed |
NCT01928758 -
Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders
|
N/A | |
Withdrawn |
NCT01847300 -
cSBI-M for Young Military Personnel
|
N/A | |
Completed |
NCT01428310 -
Study to Evaluate the Safety and Efficacy of Dietary Supplement Anatabloc in Reducing Daily Smokers' Urge to Smoke
|
Phase 1 | |
Completed |
NCT01570595 -
Positively Smoke Free on the Web (PSFW) for Smokers Living With HIV
|
Phase 1/Phase 2 | |
Recruiting |
NCT00977249 -
Varenicline for Long-term Nicotine Replacement Therapy (NRT) Users
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT00968513 -
Evaluation of Tobacco Treatment Strategies for Inpatient Psychiatry
|
Phase 3 | |
Completed |
NCT00722124 -
S-Adenosyl-L-Methionine (SAMe) for Smoking Abstinence
|
Phase 2/Phase 3 | |
Completed |
NCT00747643 -
Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
|
N/A | |
Completed |
NCT01113424 -
Bioequivalence Between Nicotine Replacement Products and Nicorette® Gum
|
N/A | |
Completed |
NCT01238627 -
Bioequivalence Between Two Oral Nicotine Sublingual Tablets, 2 mg and 4 mg
|
N/A | |
Completed |
NCT01228617 -
Single-dose Pharmacokinetics of Oral Nicotine Replacement Products
|
N/A | |
Completed |
NCT00296647 -
Smoking Cessation Intervention: Effectiveness in Primary Care
|
Phase 4 | |
Completed |
NCT00394420 -
Emergency Department Telephone Quitline
|
N/A | |
Recruiting |
NCT05487807 -
Adapting and Evaluating a Tobacco Use Cessation Program for People Living With HIV in Uganda and Zambia
|
Phase 1 | |
Completed |
NCT03553992 -
An Extended Facebook Intervention for Young Sexual and Gender Minority Smokers
|
N/A | |
Withdrawn |
NCT05440721 -
Clinical Trial of an Innovative Digital Therapeutic for Smoking Cessation With Biochemical Verification
|
N/A |